论文部分内容阅读
本文作者新近观察到数例病人以明尼苏达(Minnesota)抗淋巴母细胞球蛋白(MALG)作为免疫抑制剂应用时,导致仅在治疗期间显示免疫血液学的异常。材料和方法:作者回顾了本研究所在1982年6月至1983年4月间,为了同种移植排斥的发生接受MALG(10—20mg/kg/天iv)的23例肾移植病人,输血前标本送mayol临床血库作血清学分析。所有肾移
The authors recently observed that when a few patients were treated with Minnesota anti-lymphoblastoma globulin (MALG) as an immunosuppressive agent, they showed immunological hematologic abnormalities only during treatment. MATERIALS AND METHODS: The authors reviewed 23 renal transplant patients who underwent MALG (10-20 mg / kg / day iv) in our Institute between June 1982 and April 1983 for the allogeneic transplant rejection before transfusion Specimens sent to mayol clinical blood bank for serological analysis. All kidney transplant